OGT Appoints New Finance Director

Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced the appointment of a new finance director as part of the company’s ongoing rapid growth and expansion. Mr Tim Hall will join the company at the start of 2012 and brings a strong track record in financial management and strategic planning together with a broad knowledge of the biotech and healthcare industries. Adding further expertise to complement OGT’s skilled board and executive management team, Mr Hall joins the OGT board at a time of rapid growth and will utilise his experience to help drive the company’s ongoing expansion and development. OGT’s exceptional range of clinical genetics products, genomic and biomarker discovery services and intellectual property has driven significant and sustained growth, with customers in over 30 countries worldwide.

Dr Mike Evans, OGT’s Chief Executive Officer, commented: “We are very pleased to add someone of Tim Hall’s calibre to our already highly knowledgeable team. OGT’s commitment to investing in the best people has ensured that we have remained at the forefront of genomic research and biomarker discovery. With this new appointment we expect to continue this trend by further strengthening the level of financial strategy expertise within the company.” Mr Hall, who has a Business Administration degree from the University of Bath and qualified as an accountant with Touche Ross, has worked in the pharmaceutical and medical device industries for over 20 years. His positions have included Director of Strategic Planning at Medeva plc and Chief Financial Officer at Celltech Pharmaceuticals. Most recently, Mr Hall was Finance Director of Lombard Medical Technologies plc, a fast-growing medical device company, where he successfully led several fund-raising initiatives totalling over £62m. Commenting on his new role, Mr Hall said: “I am delighted to be joining OGT at this exciting stage in the company’s development. The OGT board of directors feel that now is the right time to bring in someone with my expertise, and I am looking forward to working with them and the management team to help contribute to the company’s ongoing successful growth and development.”

OGT was founded in 1995 by the pioneer of Southern Blotting and microarray technologies, Professor Sir Edwin Southern, and its revenues have grown over the last five years at a compound annual growth rate of over 24%. As well as developing a novel protein-based diagnostic marker discovery platform, the company has leveraged its world class expertise in microarray technology to provide high quality products and services for use in cytogenetics research, genome wide association studies and copy number variation (CNV) detection. OGT has also recently invested in developing a targeted sequencing service that combines its externally accredited laboratory practices with in-house bioinformatics know-how to turn large data sets into accurate, insightful results. The broad range of integrated services and products now offered by the company can be combined to provide the complete genomic analysis and biomarker discovery solution.

For more information about OGT’s services and products visit www.ogt.co.uk.

About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT delivers tailored biomarker discovery solutions that optimise drug and diagnostic development programmes. With expertise in genomic and proteomic diagnostic biomarkers, OGT provides highly specific customised biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.

Oxford Gene Technology, Begbroke Science Park,
Sandy Lane, Yarnton, Oxford OX5 1PF
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products@ogt.co.uk
W: www.ogt.co.uk

This release was published on openPR.